Association between SLCO1B1 gene T521C polymorphism and statin-related myopathy risk: A meta-analysis of case-control studies

Medicine (United States)

Volumn 94, Issue 37, 2015, Pages

  Hou, Qingtao ^a   Li, Sheyu ^a   Li, Ling ^a   Li, Yun ^b   Sun, Xin ^a   Tian, Haoming ^a  

^a SICHUAN UNIVERSITY   (China)

^b Third People's Hospital of Chengdu   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; ORGANIC ANION TRANSPORTER; SLCO1B1 PROTEIN, HUMAN;

ADVERSE DRUG REACTION; ALLELE; ARTICLE; CREATINE KINASE BLOOD LEVEL; DNA POLYMORPHISM; GENE FREQUENCY; GENETIC SCREENING; HUMAN; MYALGIA; MYOPATHY; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRESCRIPTION; PRIORITY JOURNAL; RHABDOMYOLYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STATIN RELATED MYOPATHY; SYSTEMATIC REVIEW; CASE CONTROL STUDY; CHEMICALLY INDUCED; GENETIC POLYMORPHISM; GENETICS; META ANALYSIS; MUSCLE DISEASE;

CASE-CONTROL STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCULAR DISEASES; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, GENETIC; SIMVASTATIN;

EID: 84941978814     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001268     Document Type: Article

References (39)

1. Jellinger PS, Smith DA, Mehta AE, et al. American Association of Clinical Endocrinologists' Guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract. 2012;18:1-78.
2. Guyton JR. Benefit versus risk in statin treatment. Am J Cardiol. 2006;97:S95-S97.
3. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med. 2009;150:858-868.
4. Sewright KA, Clarkson PM, Thompson PD. Statin myopathy: incidence, risk factors, and pathophysiology. Curr Atheroscler Rep. 2007;9:389-396.
5. Chatzizisis YS, Koskinas KC, Misirli G, et al. Risk factors and drug interactions predisposing to statin-induced myopathy. Drug Saf. 2010;33:171-187.
6. Needham M, Mastaglia F. Statin myotoxicity: A review of genetic susceptibility factors. Neuromuscul Disord. 2014;24:4-15.
7. Mastaglia FL. Iatrogenic myopathies. Curr Opin Neurol. 2010;23:45-49.
8. Ghatak A, Faheem O, Thompson PD. The genetics of statin-induced myopathy. Atherosclerosis. 2010;210:337-343.
9. Wells GA, Shea B, O'connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses.. XXX. 2000 http://www.ohri.ca/programs/clinical-epidemiol ogy/oxford.asp. Accessed June 1, 2011.
10. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603-605.
11. Higgins J, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med. 2002;21:1539-1558.
12. Hayashino Y, Noguchi Y, Fukui T. Systematic evaluation and comparison of statistical tests for publication bias. J Epidemiol. 2005:235-243.
13. Puccetti L, Ciani F, Auteri A. Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. Atherosclerosis. 2010;211:28-29.
14. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statininduced myopathy-a genomewide study. N Engl J Med. 2008;359:789-799.
15. Brunham L, Lansberg P, Zhang L, et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J. 2011;12:233-237.
16. Ferrari M, Guasti L, Maresca A, et al. Association between statininduced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2. Eur J Clin Pharmacol. 2014;70:539-547.
17. Carr DF, O'Meara H, Jorgensen AL, et al. SLCO1B1 genetic variant associated with statin-induced myopathy: A proof-of-concept study using the clinical practice research datalink. Clin Pharmacol Ther. 2013;94:695-701.
18. ∗SLCO1B1 5 gene polymorphism in statin-associated myalgias. Dermatoendocrinology. 2010;2:77-84.
19. Voora D, Shah SH, Spasojevic I, et al. The SLCO1B1 5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009;54:1609-1616.
20. Marciante KD, Durda JP, Heckbert SR, et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011;21:280-288.
21. Donnelly L, Doney A, Tavendale R, et al. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: A go-DARTS study. Clin Pharmacol Ther. 2011;89:210-216.
22. Santos PCJL, Gagliardi ACM, Miname MH, et al. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharmacol. 2012;68:273-279.
23. Hubacek JA, Dlouha D, Adamkova V, et al. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population. Med Sci Monit. 2015;21:1454-1459.
24. Melo MS, Balanco L, Branco CC, et al. Genetic variation in key genes associated with statin therapy in the Azores Islands (Portugal) healthy population. Ann Hum Biol. 2015;42:283-289.
25. Mahadevan L, Yesudas A, Sajesh PK, et al. Prevalence of genetic variants associated with cardiovascular disease risk and drug response in the Southern Indian population of Kerala. Indian J Hum Genet. 2014;20:175-184.
26. Pasternak RC, Smith SC, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002;40:567-572.
27. Keen HI, Krishnarajah J, Bates TR, et al. Statin myopathy: the fly in the ointment for the prevention of cardiovascular disease in the 21st century? Expert Opin Drug Saf. 2014;13:1227-1239.
28. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: A genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011;63:157-181.
29. Iwai M, Suzuki H, Ieiri I, et al. Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenet Genomics. 2004;14:749-757.
30. Wilke R, Ramsey L, Johnson S, et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther. 2012;92:112-117.
31. Ramsey LB, Johnson SG, Caudle KE, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther. 2014;96:423-428.
32. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009;158:693-705.
33. Pasanen M, Fredrikson H, Neuvonen P, et al. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2007;82:726-733.
34. Pasanen MK, Neuvonen M, Neuvonen PJ, et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics. 2006;16:873-879.
35. Norata GD, Tibolla G, Catapano AL. Statins and skeletal muscles toxicity: from clinical trials to everyday practice. Pharmacol Res. 2014;88:107-113.
36. McKenney JM, Davidson MH, Jacobson TA, et al. Final conclusions and recommendations of the national lipid association statin safety assessment task force. Am J Cardiol. 2006;97:S89-S94.
37. Giannakopoulou E, Ragia G, Kolovou V, et al. No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population. Mol Biol Rep. 2014;41:4631-4638.
38. Pasanen MK, Neuvonen PJ, Niemi M. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics J. 2008;9:19-33.
39. Santos PC, Soares RA, Nascimento RM, et al. SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group. BMC Med Genet. 2011;12:136.